Stocktoria
Zomedica Corp. ZOMDF
OTC · stock · Pharmaceutical Preparations · website · IPO 2013-10-28
Zomedica Corp. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $32.0M | $27.3M | $25.2M | $18.9M | $4.1M | $0 | — | — | — | — |
| Gross profit | $21.7M | $19.1M | $17.3M | $13.5M | $3.1M | $0 | — | — | — | — |
| R&D expense | $7.2M | $7.3M | $5.7M | $2.6M | $1.7M | $8.0M | $10.3M | $10.3M | $2.8M | $1.5M |
| SG&A expense | — | — | — | $33.0M | $22.8M | $8.7M | — | — | — | — |
| Operating income | -$84.4M | -$51.1M | -$43.3M | -$21.9M | -$21.4M | -$16.8M | -$19.8M | -$16.6M | -$8.1M | -$5.7M |
| Interest expense | — | — | $50,000 | $1,000 | $6,000 | $732 | $18,338 | — | — | — |
| Income tax | -$278,000 | -$557,000 | -$1.3M | -$2.4M | -$2.3M | $0 | — | — | — | — |
| Net income | -$81.9M | -$47.0M | -$34.5M | -$17.0M | -$18.4M | -$16.9M | -$19.8M | -$16.6M | -$8.1M | -$5.7M |
| EPS (diluted) | $-0.08 | $-0.05 | $-0.04 | $-0.02 | — | — | — | — | — | — |
| Operating cash flow | -$17.6M | -$23.6M | -$16.0M | -$11.7M | -$14.3M | -$16.2M | -$15.6M | -$11.1M | -$7.1M | -$4.6M |
| Free cash flow | -$18.2M | -$28.8M | -$27.3M | -$12.5M | -$14.4M | -$16.3M | -$15.8M | -$11.8M | -$7.3M | -$4.8M |
| Cash & equivalents | $9.0M | $7.0M | $13.0M | $27.4M | $195.0M | $62.0M | $510,586 | $1.9M | $3.4M | $3.2M |
| Inventory | $5.5M | $5.1M | $5.1M | $2.7M | $2.8M | $0 | — | — | — | — |
| Total assets | $127.0M | $207.4M | $253.2M | $279.6M | $280.4M | $66.1M | $4.2M | $6.0M | $5.2M | $4.6M |
| Total liabilities | $11.6M | $11.7M | $13.2M | $12.2M | $9.5M | $3.1M | $2.1M | — | — | — |
| Shareholders' equity | $115.4M | $195.7M | $240.0M | $267.4M | $270.9M | $51.1M | $2.1M | $3.7M | $4.4M | $3.8M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +17.4% | +8.3% | +33.0% | +358.0% | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.